Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - IMPATH Inc. (NasdaqNM:IMPH)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options
Location
521 West 57th Street, 6th Floor
New York, NY 10019
Phone: (212) 698-0300
Fax: (212) 698-0305
Email: iris.daniels@impath.com
Employees (last reported count): 889
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Healthcare Facilities
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 600 SmallCap
Ownership
·Insider and 5%+ Owners: 23%
·Over the last 6 months:
 · one insider buy; 1,000  shares
 · 2 insider sells; 3,000  shares
·Institutional: 79% (103% of float)
(250 institutions)
·Net Inst. Buying: 177.0K shares (+1.38%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
IMPATH Inc. focuses on the clinical application of advanced technologies in the community-based hospital environment to enable clinicians to make better treatment decisions for their cancer patients. The Company expanded its focus to harness the information it was generating from performing analyses on thousands of cancer specimens annually, and to broaden the value applications of that biological information. The Company has also completed multiple strategic acquisitions that have provided technologies; complementary cancer information including longitudinal treatment and outcomes data; pharmacoeconomic analytical capabilities, and a tissue and serology archive of well-characterized, fully documented cancer specimens. IMPATH serves the oncology community through three operating divisions: Physician Services, IMPATH Predictive Oncology (formerly BioPharmaceutical/Genomics Services (Biopharma) and Information Services.
More from Market Guide: Expanded Business Description

Financial Summary
IMPATH provides patient-specific cancer diagnostic and prognostic information, with a particular expertise in difficult to diagnose tumors, prognostic profiles in breast and other cancers, and lymphoma/leukemia analysis. For the six months ended 6/30/01, revenues rose 40% to $89.2 million. Earnings rose 42% to $8.3 million. Results reflect an increase in the case volumes of physician services, higher revenue realization per case, and the Company's streamlining efforts.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Anu Saad, Ph.D., 44
Chairman, CEO
$521K--  
Richard Adelson, 35
Pres, COO
347K$1.3M
David Cammarata, 37
CFO
238K1.3M
James Douglass, Ph.D., 51
CIO
283K194K
Richard Rosenzweig, 34
Gen. Counsel, Sec.
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:IMPHAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Apr-2001
$28.75 
Recent Price$43.00 
52-Week High
on 3-Nov-2000
$81.563
Beta-0.14 
Daily Volume (3-month avg)218.8K
Daily Volume (10-day avg)170.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+22.9%
52-Week Change
relative to S&P500
+64.8%
Share-Related Items
Market Capitalization$688.8M
Shares Outstanding16.0M
Float12.3M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 29-Aug-2000
Per-Share Data
Book Value (mrq)$9.28 
Earnings (ttm)$0.92 
Earnings (mrq)$0.26 
Sales (ttm)$9.82 
Cash (mrq)$1.37 
Valuation Ratios
Price/Book (mrq)4.63 
Price/Earnings (ttm)46.54 
Price/Sales (ttm)4.38 
Income Statements
Sales (ttm)$163.5M
EBITDA (ttm)$38.3M
Income available to common (ttm)$15.4M
Profitability
Profit Margin (ttm)9.4%
Operating Margin (ttm)15.4%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)7.98%
Return on Equity (ttm)11.22%
Financial Strength
Current Ratio (mrq)2.86 
Debt/Equity (mrq)0.31 
Total Cash (mrq)$21.9M
Short Interest
As of 8-Aug-2001
Shares Short1.31M
Percent of Float10.6%
Shares Short
(Prior Month)
1.32M
Short Ratio5.21 
Daily Volume251.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.